Presidential Symposium

Precision Oncology

Future Challenges in Development of Precision Medicine

Asian International Collaboration Symposium

Current Status and Future Perspectives for Biliary Tract Cancer in Asian Countries

Challenges of Breast Cancer Research Collaboration Across Asia

Facilitation of Asian Collaboration in Cancer Clinical Trials

ASCO-JSMO Breakthrough Summit

JSMO-ASCO Breakthrough Summit Insights: Artificial Intelligence in Oncology and Therapeutics

Special Session

Impact of COVID-19 on Clinical Practice and Research in Oncology

Joint Symposium

ASCO/JSMO Joint Symposium

AI Oncology: Development Status and Perspectives

ESMO/JSMO Joint Symposium

Liquid Biopsy for Clinical Implementation

Asia-Pacific/JSMO Joint Symposium

CAR-T and New Generation Therapy in Asia-Pacific

SIOG/JSMO Joint Symposium

The Geriatric Oncology, Past, Present and Future


Gastrointestinal Cancer

Future Perspectives of Immunotherapy for mCRC

Present Status and Future Perspectives of Immunotherapy for Advanced Gastric Cancer

Present Status and Future Perspectives of Immunotherapy for Advanced Esophageal Cancer

Hepatobiliary/Pancreatic Cancer

The Cutting-Edge on Perioperative Treatment for Pancreatic Cancer

Lung Cancer/Thoracic Cancer

Challenges of Combination Immunotherapy for Lung Cancer

Perspectives in Translational Biomarker Research for Immune Checkpoint Inhibitors

Future Prospects of Molecular Targeted Therapy for Lung Cancer Patients with Driver Mutation

Hematologic Malignancies

Cutting Edge of AML Treatment

Antibody Drug Conjugates for Hematologic Malignancies

MRD-guided Therapies for Hematologic Malignancies

Breast Cancer

Development and Future Perspectives of Immune Checkpoint Inhibitors for Breast Cancer

De-escalating and Escalating Treatment for Breast Cancer

Gynecologic Cancer

PARP Inhibitor, Anti-angiogenesis, or Both? -Best Combination for Ovarian Cancer-

Immune Checkpoint Blockade for Gynecological Malignancy

Genitourinary Cancer

A New Era of Genitourinary Cancer Precision Medicine

Head and Neck Cancer

New Perspectives in Treatment of Head and Neck Cancer

New Perspectives in Treatment of Thyroid Cancer

Rare Cancer/Cancer of Unknown Primary

Immunotherapy and Target Therapy for Rare Cancers

Translational Research/Clinical Pharmacology

Advances in Molecular Therapeutics: Potential Targets and New Strategies

Immuno-oncology: Tumor Microenvironment and Genomic Alterations

Cross-sectional Program

Targeting Tumor Microenvironment and Microbiome in the New Era of Cancer Immunotherapy

Tumor Agnostic Drug Development and Approval
- New Phase for Oncology Precision Medicine –

Clinical Trial Facilitation Program

Adjuvant Clinical Trials in the Precision Medicine Era

Patient Advocacy/Survivorship

Implementation Strategies of Cancer Survivorship Care

Meet the Experts

Gastrointestinal Cancer

Changing Strategy of Systemic Treatment of AGC

Novel Targets in Colorectal Cancer: BRAF, HER2, KRAS and Beyond

Hepatobiliary/Pancreatic Cancer

Why Is Biliary Tract Cancer Special?

Lung Cancer/Thoracic Cancer

Fostering Next Generation in Medical Oncology: ESMO Perspective

Novel Strategies Overcoming Resistance Mechanisms in Non-small Cell Lung Cancer with Driver Oncogene Mutations

Hematologic Malignancies

Treatment Options in Relapsed / Refractory MM

Breast Cancer

What Is the Role of Immunotherapy for MBC? -Beyond TNBC-

How Can Young Oncologists Develop Their Career in Breast Oncology?

Gynecologic Cancer

What Is the Optimal PARP Inhibitor for Ovarian Cancer Patients?

Genitourinary Cancer

State of the Art Management of Metastatic Urothelial Cancer in 2021

Head and Neck Cancer

Future Directions for the Treatment of Head and Neck Cancer

Rare Cancer/Cancer of Unknown Primary

Molecular Target Therapy for Soft Tissue Sarcoma

Translational Research/Clinical Pharmacology

Resistance Mechanisms to CDK4/6 Inhibitors in Breast Cancer or Novel Therapeutic Strategies against Breast Cancer Harboring HER2 Aberrations

State-of-the-art and Novel Molecular Targeted Therapies in Non-small-cell Lung Cancer

Tumor Microenvironment in Renal Cell Carcinoma and Its Impact on Immunotherapy

Cross-sectional Program

Aiming to Overcome Immunotherapy Resistance

Precision Medicine Becomes Reality:Tumor-Agnostic Oncology Drug Development

Clinical Trial Facilitation Program


Patient Advocacy/Survivorship

Improving Care and Outcomes for Cancer Survivors: an Australian Experience

Page Top

Page top